Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Pasithea Therapeutics Corp. (KTTA)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”) a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that members of its management team will deliver a company presentation at the H.C. Wainwright 26th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in Midtown Manhattan, New York. Pasithea´s presentation will be available online for conference participants beginning at 7:00 a.m. Eastern Time on Monday, September 9th. Management will also conduct 1x1 meetings in NYC from September 9th through September 11th. Registration and other information about the event can be found at https://hcwevents.com/annualconference/. About Pasithea Therapeutics Corp. Pasithea is a biotechnology company foc
Show less
Read more
Impact Snapshot
Event Time:
KTTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KTTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KTTA alerts
High impacting Pasithea Therapeutics Corp. news events
Weekly update
A roundup of the hottest topics
KTTA
News
- Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer [Yahoo! Finance]Yahoo! Finance
- Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerGlobeNewswire
- Pasithea Therapeutics files to sell 3.74M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswire
- Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer [Yahoo! Finance]Yahoo! Finance
KTTA
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 10-Q
- 10/15/24 - Form EFFECT
- KTTA's page on the SEC website